Under the new Hospital Outpatient Prospective Payment System Final Rule, CMS will package the reimbursement for certain products used in advanced wound care with the related surgical procedure into a two-tier payment system.
MiMedx Group is an integrated developer, manufacturer and marketer of regenerative biomaterials and bioimplants processed from human amniotic membrane.
More Articles on Supply Chain:
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics’ Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation
